|Dr. Brian Russell Wong||CEO, Pres & Director||912.2k||N/A||1972|
|Mr. Rodney K. B. Young||CFO & Sec.||132.08k||N/A||1963|
|Dr. Dirk G. Brockstedt Ph.D.||Chief Scientific Officer||427.77k||N/A||1969|
|Steve Young Ph.D.||VP of Technology||N/A||N/A||N/A|
|Ms. Phyllis Loud Gray||VP of HR||N/A||N/A||N/A|
|Dr. Paul Kassner||Sr. VP of Quantitative & Computational Biology||N/A||N/A||1967|
|Dr. David Wustrow||Sr. VP of Drug Discovery & Preclinical Devel.||N/A||N/A||1959|
|Dr. William Ho||Chief Medical Officer||N/A||N/A||1965|
|Ms. Karen C. Lam||VP of Fin. & Corp. Controller||N/A||N/A||1974|
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.